|
| Press Releases |
|
 |
|
| Monday, October 10, 2022 |
|
|
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China |
| Hua Medicine (the "Company", HKEx Stock Code: 2552.HK) today announces that the New Drug Application (NDA) of HuaTangNing (dorzagliatin tablets, HMS5552), a first-in-class glucokinase activator (GKA) developed by the Company has been approved by the National Medical Products Administration (NMPA) of China on October 8th for two indications more info >> |
|
| Tuesday, June 7, 2022 |
|
|
Hua Medicine Announces Dorzagliatin can Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM and GCK-MODY Patients at ADA 2022 |
| Hua Medicine (the "Company", stock code: 2552.HK) today announces that several clinical findings were presented on its global first-in-class drug, glucokinase activator (GKA) dorzagliatin, at the 82nd American Diabetes Association (ADA) Annual Scientific Sessions. more info >> |
|
| Friday, May 13, 2022 |
|
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
| Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
| Thursday, March 17, 2022 |
|
|
Hua Medicine Announces 2021 Annual Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
| Sunday, September 26, 2021 |
|
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
| Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
| Friday, December 18, 2020 |
|
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Hong Kong Watch & Clock Fair, Salon de TIME return in September
Aug 31, 2025 12:30 JST
|
|
|
Genetec reinforces foundation for growth, maintains resilient outlook
Aug 30, 2025 23:59 HKT/SGT
|
|
|
Integrated Development of Four Major Businesses to Drive the Financial 'Five Major Areas', GF Securities Announces its 2025 Interim Results
Aug 30, 2025 16:08 HKT/SGT
|
|
|
Global New Material International Establishes Asia-Pacific Headquarters in Hangzhou, Advancing Global Integration
Aug 30, 2025 10:54 HKT/SGT
|
|
|
Gome Retail's H1 2025 Significant Performance Improvement, Debt Resolution Breakthrough, and Accelerated Strategic Transformation
Aug 29, 2025 22:15 HKT/SGT
|
|
|
CITIC Limited reports solid H1 2025 results with higher dividend
Aug 29, 2025 20:51 HKT/SGT
|
|
|
AI-Powered Foundation, Innovation-Driven Empowerment, Legend Holdings Reports RMB699 Million in Net Profit Attributable to Parent for 2025H1
Aug 29, 2025 19:13 HKT/SGT
|
|
|
Honda Announces New Plan for Relocation of Global Head Office to Yaesu Area in Tokyo and Reconstruction of Honda Aoyama Building
Aug 29, 2025 18:54 JST
|
|
|
Analogue 2025 Interim Results Net Profit Reaches HK$80.8 Million
Aug 29, 2025 17:42 HKT/SGT
|
|
|
Black Spade calls for family offices to increase their focus on digital assets and emerging industries 
Aug 29, 2025 17:32 HKT/SGT
|
|
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma
Aug 29, 2025 18:17 JST
|
|
|
TechInnovation 2025 Returns with 3 Days of Game-Changing Innovation
Aug 29, 2025 16:00 HKT/SGT
|
|
|
Hitachi Energy acquires remaining stake of eks Energy, reinforcing leadership in power conversion systems for energy storage
Aug 29, 2025 15:17 JST
|
|
|
JF SmartInvest Holdings Ltd Returns to Profit in 2025 Interim Results
Aug 29, 2025 11:24 HKT/SGT
|
|
|
Fosun's Bold Innovation & Globalization Drive Valuation Upside
Aug 29, 2025 10:14 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
